Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A4

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 27, 2005
 
MARKETSHARE RECOVERY, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
0-15807
  
31-1190725
(State of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
         
 
33 South Service Road, Suite 111
Jericho, NY 11753
(Address of Principal Executive Offices)


(516) 750-9733
(Registrant's telephone number, including area code)
 
  
95 Broadhollow Road, Suite 101
Melville, NY 11747
(former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.24d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.23e-4(c))
 

EXPLANATORY NOTE

bioMETRX, Inc. is filing this Amendment No. 4 to its Current Report on Form 8-K originally field with the Securities and Exchange Commission (“SEC”) on June 3, 2005, and the amendments to this Form 8-K filed on June 8, 2005, September 1, 2005 and November 30, 2005. We are only filing herewith revised proforma financial information. Accordingly, unless otherwise expressly stated, this Amendment No. 4 does not reflect events occurring after the filing of the original 8-K or modify or update in any way disclosures contained in the original Form 8-K.

Item 9.01 Financial Statements and Exhibits

The Financial Statement required by Item 310 of Regulation S-B is stated in U.S. dollars and are prepared in accordance with U.S. Generally Accepted Accounting Principles.

(a) Financial Statements of bioMetrx Technologies, Inc.

·  
Report of Independent Registered Public Accounting Firm*

·  
Balance Sheets as of December 31, 2004 and March 31, 2005 (unaudited).*

·  
Statement of operations for the years ended December 31, 2004 and 2003 and the period from February 1, 2001 (inception) to March 31, 2005 unaudited and three months ended March 31, 2005 (unaudited).*

·  
Statements of cash flows for the years ended December 31, 2004 and 2003 and the period from February 1, 2001 (inception) to March 31, 2005 unaudited and for the three months ended March 31, 2005 (unaudited).*

·  
Statements of changes in stockholders' equity for the period from February 1, 2001 (inception) to December 31, 2004 and for the three months ended March 31, 2005 (unaudited).*

·  
Notes to Financial Statements*

(b) Pro Forma Financial Information

·  
Unaudited Pro forma condensed combined balance sheet as of March 31, 2005.**
 
·  
Unaudited Pro forma combined condensed statement of operations for the year ended December 31, 2004 and March 31, 2005.*
 
·  
Unaudited Pro forma combined condensed statement of operations for the three months ended March 31, 2005**
 
·  
Notes to pro forma condensed combined financial statements.**
 
2
 
(c) Exhibits

 
2.1
Agreement and Plan of Merger dated as of April 27, 2005 (Incorporated by reference to Exhibit 10.1 to our Form 8-K report dated April 27, 2005)

 
99.1
Press Release dated May 31, 2005 (Incorporated by reference to Exhibit 99.1 to our Form 8-K/A report dated May 27, 2005)

 
99.2
Descriptive Memorandum dated June 8, 2005*

__________________
* Previously filed.

** Filed herewith.
3

 
MARKETSHARE RECOVERY, INC. & SUBSIDIARIES       
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET       
March 31, 2005      
(Unaudited)
                               
   
Marketshare
Recovery Inc.
 
Biometrx
Technologies, Inc.
 
 
 
Pro Forma
Dr.
 
 
 
Adjustments
Cr.
 
Pro Forma
Balances
 
                               
ASSETS
                              
Current Assets:
                              
                               
Cash
    
-
   
299,354
   
3
    
25,000
               
324,354
 
Cash in Escrow
    
45,000
   
-
                           
45,000
 
Restricted Cash
    
-
   
275,000
                           
275,000
 
Marketable Securities
    
6,545
   
-
                           
6,545
 
Due from Related Party
    
-
   
75,000
               
5
    
75,000
   
-
 
Loans Receivable- Stockholder
    
-
   
231,404
               
 
          
231,404
 
                                             
Total Current Assets
    
51,545
   
880,758
               
 
          
882,303
 
                             
 
              
Other Assets:
                            
 
              
Security Deposit
    
-
   
2,860
               
 
          
2,860
 
                                             
TOTAL ASSETS
  
$
51,545
  
$
883,618
                            
885,163
 
                                             
LIABILITIES AND
STOCKHOLDERS' EQUITY
                                            
                                             
Current Liabilities:
                                            
                                             
Loan Payable- Stockholder
    
109,736
   
-
                           
109,736
 
Advances on Letter of Intent
    
75,000
   
-
   
5
    
75,000
               
-
 
Accrued Expenses
    
180,940
   
73,426
                           
254,366
 
Accrued Taxes Payable
    
-
   
40,989
                           
40,989
 
Accrued Payroll
    
-
   
835,000
   
3
    
470,000
               
365,000
 
Commissions Payable
    
-
   
105,000
                           
105,000
 
                                             
Total Current Liabilities
    
365,676
   
1,054,415
                           
875,091
 
                                             
Stockholders' Deficit
                                            
 
                                            
Common Stock $.001 par value:
50,000,000 shares authorized:
3,806,221 shares issued and
outstanding
                                            
Common Stock $.001 par value:
20,000,000 shares authorized:
11,070,730 shares issued and
outstanding
    
3,806
   
11,071
   
2
    
2,208
   
1
    
14,218
   
15,816
 
                 
4
    
12,576
   
3
    
1,505
       
 
                
 
          
 
              
Additional Paid-In-Capital
   
1,902,954
   
1,713,679
   
1
    
14,218
   
2
    
2,208
   
2,389,803
 
                 
3
    
10,000
   
3
    
1,003,495
       
                 
4
    
1,890,944
   
 
              
                 
4
    
317,371
   
 
              
 
    
 
    
 
    
 
          
 
          
 
  
Accumulated Deficit
   
(2,220,891
)
  
(1,895,547
)
  
3
    
500,000
   
4
    
2,220,891
   
(2,395,547
)
                 
 
                          
Total Stockholders' Deficit
    
(314,131
)
  
(170,797
)
  
 
                      
10,072
 
                 
 
                          
Total Liabilities and
Stockholders' Deficit
  
$
51,545
  
$
883,618
    
 
    
3,317,317
         
3,317,317
   
885,163
 
                 
 
                          

4
 

MARKETSHARE RECOVERY, INC. & SUBSIDIARY
PROFORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
For the Three Months Ended March 31, 2005
(Unaudited)
                   
   
Marketshare
Recovery Inc.
 
Biometrx
Technologies, Inc.
 
Pro Forma Adjustments
 
Pro Forma
Balances
 
                   
REVENUES
  
$
-
  
$
-
  
$
-
  
$
-
  
                           
                           
Expenses:
                          
General and Administrative Expenses
    
46,636
   
285,816
         
332,452
 
Research and Development Expenses
    
-
   
32,362
         
32,362
 
Total Operating Expenses
   
46,636
   
318,178
   
-
   
364,814
 
                           
Operating Loss
    
(46,636
)
  
(318,178
)
  
-
   
(364,814
)
                           
Other Expenses
                          
Interest Expense- Stockholder
    
(2,165
)
              
(2,165
)
Unrealized Loss on Marketable Securities
   
(14,847
)
  
-
   
-
   
(14,847
)
                           
Total Other Expenses
    
(17,012
)
  
-
   
-
   
(17,012
)
                           
Net Loss
  
$
(63,648
)
$
(318,178
)
$
-
  
$
(381,826
)
                           
Weighted Average Common Shares Outstanding
                      
12,675,443
 
                           
Net Loss per Common Share (Basic and Diluted)
                    
$
(0.03
)
                           


5
MARKETSHARE RECOVERY, INC. AND SUBSIDIARIES
NOTES TO THE UNAUDITED PRO FORMA FINANCIAL STATEMENTS


The following adjustments to the unaudited pro forma consolidated financial statements as of March 31, 2005 reflects the issuance of 14,218,424 shares of the Company’s common stock for the acquisition of all of the outstanding capital stock of bioMetrx Technologies, Inc. (“bioMetrx”) and that the transaction occurred as of March 31, 2005:


1.  
To reflect the issuance of 14,218,424 shares of the Company’s common stock for the acquisition of all of the outstanding capital stock of bioMetrx.

2.  
To reflect the cancellation of 2,208,251 shares of Marketshare’s common stock.

3.  
To reflect the issuance of 1,505,000 shares of bioMetrx common stock during the period April and May 2005.

4.  
To reflect the recapitalization of the reverse merger. For financial accounting purposes, the exchange of stock will be treated as a recapitalization of Marketshare Recovery, Inc. with the former shareholders of the Company retaining 1,597,700 or approximately 10% of the outstanding stock.

5.  
To eliminate intercompany accounts.


 1          
Additional Paid-In Capital
    
14,218
    
Common Stock
    
 
  
14,218
           
 2           
Common Stock - Marketshare
    
2,208
    
Additional Paid-In Capital
    
 
  
2,208
           
 3          
Cash
  
 
25,000
    
Additional Paid-In Capital
    
10,000
    
Accrued Salaries
    
470,000
    
S,G & A Expenses
    
500,000
    
Common Stock
  
 
 
  
1,505
Additional Paid-In Capital
    
 
  
1,003,495
           
 4          
Common Stock - bioMetrx
    
12,576
    
Additional Paid-In Capital - Marketshare
    
1,890,944
    
Additional Paid-In Capital - biometrx
    
317,371
    
Accumulated Deficit - Marketshare
    
 
  
2,220,891
           
 5          
Advances on Letter of Intent
    
75,000
    
Due from Related Party
    
 
  
75,000

 
6
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  BIOMETRX, INC.
 
 		  
 		  
 
  By:   /s/ Mark Basile
 
Mark Basile, CEO
Dated: February 9, 2007 Title 

 
7